Denmark-based Xellia Pharmaceuticals is investing EUR 70.85 million in Szigetszentmiklós, south of Budapest, further strengthening Hungary's role in the European healthcare and antibiotic supply chain. The development aims to create a modern, automated pharmaceutical manufacturing plant and promises create 91 new high value-added jobs.
Headquartered in Copenhagen, Xellia Pharmaceuticals is a specialty pharmaceutical company focused on producing anti-infective medicines and providing critical care therapies. It operates three state-of-the-art manufacturing facilities in Denmark, Hungary and China, as well as R&D centers in Norway.
The EUR 70.85 million investment will establish a high-tech, automated pharmaceutical manufacturing plant where the company will produce products based on antibiotic active ingredients classified as critical by the European Union and the WHO. Production will take place using specialized drying and packaging technologies.
As part of the development, warehouse capacity, utility systems and modern office infrastructure will also be built to support modern, high-precision manufacturing processes.
The company is a market leader in anti-infective medicines and serves around 500 pharmaceutical partners worldwide.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Genius Automotive Hungarian Subsidiary's CEE Expansion November 2, 2025
